QIAGEN (QGEN) announced that Clarient, a GE Healthcare (GE) company, has adopted the use of the therascreen KRAS RGQ PCR Kit as a companion diagnostic to guide the use of Erbitux as a treatment in patients with metastatic colorectal cancer. Clarient, with a customer base of more than 2,000 pathologists, oncologists, clinical laboratories and hospitals, selected QIAGEN's therascreen KRAS test and QIAGEN's Rotor-Gene Q MDx instrument following the FDA approval of the test in July 2012. Clarient joins a rapidly growing number of laboratories switching from laboratory-developed tests to the FDA-approved therascreen KRAS test for diagnostic testing for late stage colorectal cancer.
- Pharmaceuticals & Drug Trials
- GE Healthcare